| abstract |
FIELD: medicine. n SUBSTANCE: invention relates to application of formula (I) compound, for preparation of medication, used for treatment of chronic obstructive pulmonary disease. In compound (I) A represents aryl group, selected from phenyl; B represents aryl group, selected from phenyl or pyridyl; X represents carbon atom or nitrogen atom; R represents substituted or non-substituted groups, selected from heteroaryl groups, including pyridyl, thienyl, furyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidinyl and pyrazinyl, and heterocyclic groups, including morpholine, thiomorpholine, piperazine, piperidine, piperidin-4-one, pyrrolidine, pyrrole-2,5-dione, thiazolidine, 1-oxido-thiazolidine and 1,1-dioxido-1,3-thiazolidine; where heterocyclic group is optionally substituted with substituents, independently selected from substituted or non-substituted (C 6 )aryl, -CH 2 -C 6 aryl, -CH 2 -heteroaryl, CO-C 6 aryl, -CO-heteroaryl, -CS-heteroaryl, -CO-C 3 - 6 cycloalkyl, cyano(C 1-4 )alkyl, -O-methyloxime, -SO 2 Cl, formyl, or other substituted or non-substituted heterocyclic group, selected from pyridyl, pyrimidinyl and piperidinyl; where binding of heterocyclic group to pyrimidine ring takes place through carbon or nitrogen atom; and where group R or substituent of heterocyclic group R are optionally substituted. Other substituents are given in invention formula. n EFFECT: compounds are suitable for treatment of immunological diseases, inflammation, pain impairment, rheumatoid arthritis; osteoporosis, multiple myeloma, uveitis, acute and chronic myelogenous leukaemia; atherosclerosis, cancer, cachexia and other diseases. n 15 cl, 15 tbl, 158 ex |